These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26374204)

  • 21. Increased TCA cycle activity and reduced oxygen consumption during cytochrome P450-dependent biotransformation in fission yeast.
    Dragan CA; Blank LM; Bureik M
    Yeast; 2006 Aug; 23(11):779-94. PubMed ID: 16921551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of cytochrome P450 3A7 in Escherichia coli: effects of 5' modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase.
    Gillam EM; Wunsch RM; Ueng YF; Shimada T; Reilly PE; Kamataki T; Guengerich FP
    Arch Biochem Biophys; 1997 Oct; 346(1):81-90. PubMed ID: 9328287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineering bacterial cytochrome P450 (P450) BM3 into a prototype with human P450 enzyme activity using indigo formation.
    Park SH; Kim DH; Kim D; Kim DH; Jung HC; Pan JG; Ahn T; Kim D; Yun CH
    Drug Metab Dispos; 2010 May; 38(5):732-9. PubMed ID: 20100815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The steroid metabolite 16(β)-OH-androstenedione generated by CYP21A2 serves as a substrate for CYP19A1.
    Neunzig J; Milhim M; Schiffer L; Khatri Y; Zapp J; Sánchez-Guijo A; Hartmann MF; Wudy SA; Bernhardt R
    J Steroid Biochem Mol Biol; 2017 Mar; 167():182-191. PubMed ID: 28065637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Formation of indigo by recombinant mammalian cytochrome P450.
    Gillam EM; Aguinaldo AM; Notley LM; Kim D; Mundkowski RG; Volkov AA; Arnold FH; Soucek P; DeVoss JJ; Guengerich FP
    Biochem Biophys Res Commun; 1999 Nov; 265(2):469-72. PubMed ID: 10558891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved product-per-glucose yields in P450-dependent propane biotransformations using engineered Escherichia coli.
    Fasan R; Crook NC; Peters MW; Meinhold P; Buelter T; Landwehr M; Cirino PC; Arnold FH
    Biotechnol Bioeng; 2011 Mar; 108(3):500-10. PubMed ID: 21246504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterologous biosynthesis of triterpenoid dammarenediol-II in engineered Escherichia coli.
    Li D; Zhang Q; Zhou Z; Zhao F; Lu W
    Biotechnol Lett; 2016 Apr; 38(4):603-9. PubMed ID: 26739962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterologous caffeic acid biosynthesis in Escherichia coli is affected by choice of tyrosine ammonia lyase and redox partners for bacterial Cytochrome P450.
    Haslinger K; Prather KLJ
    Microb Cell Fact; 2020 Feb; 19(1):26. PubMed ID: 32046741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Production of human cytochrome P450 2D6 drug metabolites with recombinant microbes--a comparative study.
    Geier M; Braun A; Emmerstorfer A; Pichler H; Glieder A
    Biotechnol J; 2012 Nov; 7(11):1346-58. PubMed ID: 22930520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of engineered cytochrome P450 mutants as biocatalysts for the synthesis of benzylic and aromatic metabolites of fenamic acid NSAIDs.
    Venkataraman H; Verkade-Vreeker MC; Capoferri L; Geerke DP; Vermeulen NP; Commandeur JN
    Bioorg Med Chem; 2014 Oct; 22(20):5613-20. PubMed ID: 24999003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design of a cytochrome P450BM3 reaction system linked by two-step cofactor regeneration catalyzed by a soluble transhydrogenase and glycerol dehydrogenase.
    Mouri T; Shimizu T; Kamiya N; Goto M; Ichinose H
    Biotechnol Prog; 2009; 25(5):1372-8. PubMed ID: 19725101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional and structural consequences of a novel point mutation in the CYP21A2 gene causing congenital adrenal hyperplasia: potential relevance of helix C for P450 oxidoreductase-21-hydroxylase interaction.
    Riepe FG; Hiort O; Grötzinger J; Sippell WG; Krone N; Holterhus PM
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2891-5. PubMed ID: 18445671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective steroid oxyfunctionalisation by CYP154C5, a bacterial cytochrome P450.
    Bracco P; Janssen DB; Schallmey A
    Microb Cell Fact; 2013 Oct; 12():95. PubMed ID: 24134652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P450(BM-3)-catalyzed whole-cell biotransformation of alpha-pinene with recombinant Escherichia coli in an aqueous-organic two-phase system.
    Schewe H; Holtmann D; Schrader J
    Appl Microbiol Biotechnol; 2009 Jul; 83(5):849-57. PubMed ID: 19266193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Production of bioactive hydroxyflavones by using monooxygenase from Saccharothrix espanaensis.
    Lee H; Kim BG; Ahn JH
    J Biotechnol; 2014 Apr; 176():11-7. PubMed ID: 24560623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preparation and characterization of a 5'-deazaFAD T491V NADPH-cytochrome P450 reductase.
    Zhang H; Gruenke L; Saribas AS; Im SC; Shen AL; Kasper CB; Waskell L
    Biochemistry; 2003 Jun; 42(22):6804-13. PubMed ID: 12779335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A gene-fusion approach to enabling plant cytochromes p450 for biocatalysis.
    Schückel J; Rylott EL; Grogan G; Bruce NC
    Chembiochem; 2012 Dec; 13(18):2758-63. PubMed ID: 23129550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytochrome P450 reductase from Candida apicola: versatile redox partner for bacterial P450s.
    Girhard M; Tieves F; Weber E; Smit MS; Urlacher VB
    Appl Microbiol Biotechnol; 2013 Feb; 97(4):1625-35. PubMed ID: 22526787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-cell biotransformation with recombinant cytochrome P450 for the selective oxidation of Grundmann's ketone.
    Hernández-Martín A; von Bühler CJ; Tieves F; Fernández S; Ferrero M; Urlacher VB
    Bioorg Med Chem; 2014 Oct; 22(20):5586-92. PubMed ID: 25023538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reaction and catalyst engineering to exploit kinetically controlled whole-cell multistep biocatalysis for terminal FAME oxyfunctionalization.
    Schrewe M; Julsing MK; Lange K; Czarnotta E; Schmid A; Bühler B
    Biotechnol Bioeng; 2014 Sep; 111(9):1820-30. PubMed ID: 24852702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.